C. Shi

发表

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

Deepak L. Bhatt, E. Topol, Jersey Chen, 2011, The Canadian journal of cardiology.

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Deepak L. Bhatt, E. Topol, Jersey Chen, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.

G. Stone, M. York, A. Lincoff, 2008, Journal of the American College of Cardiology.

Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial

M. Carey, K. Strojek, S. Jacober, 2010, Diabetes, obesity & metabolism.

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

T. Hardy, H. Fu, D. Moller, 2015, Diabetes Care.

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

T. Hardy, H. Fu, D. Moller, 2016, Diabetes Care.

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes

H. Fu, R. Kelly, W. Landschulz, 2015 .

A Randomized , Double-Blind , Placebo-Controlled Phase 2 Study of the Glucagon Receptor Antagonist LY 2409021 in Patients With Type 2 Diabetes

H. Fu, R. Kelly, W. Landschulz, 2015 .

Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial

Ameet Bakhai, Chunxue Shi, Tara Lavelle, 2004, Circulation.

Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents

G. Breithardt, P. Teirstein, A. J. O’Malley, 2005, Circulation.

Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis.

D. Holmes, D. Cohen, M. Reynolds, 2007, American heart journal.

Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial.

J. Moses, M. Leon, S. Ellis, 2006, Journal of the American College of Cardiology.

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.

G. Stone, S. Ellis, T. Lavelle, 2006, Journal of the American College of Cardiology.

Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trial

J. Moses, M. Leon, D. Cohen, 2003 .

A novel strategy of high oxygen vacancy concentration regulation for promoting the formation of nonradical species in the directional activation of peroxymonosulfate

Liwen Xiao, Qingge Feng, C. Shi, 2023, Chemical Engineering Journal.

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

T. Hardy, H. Fu, D. Moller, 2017, Diabetes Care.

Synergistic effect of iron and nitrogen on porous carbon to improve electron transfer efficiency resulting in the enhancement of tetracycline hydrochloride removal

C. Shi, Zheng Liu, Xingjing Yang, 2023, Diamond and Related Materials.

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.

M. York, A. Lincoff, R. Mehran, 2008, Journal of the American College of Cardiology.